QBD based Design and Characterization of Proniosomal Transdermal Delivery of Atenolol and Glibenclamide Combination: An Innovative Approach

Abstract

There are numerous circumstances where chronic disease is associated with other disorders, especially in diseases like diabetes with noncommunicable disease risk factors, such as hypertension. This study shows a novel and innovative combinational proniosomal delivery of combination to beat the reactions by complex therapeutic regimen, and to improve patient compliance after controlling combinational transdermal delivery of Glibenclamide (GLB) and Atenolol (ATN) which have not been tried actually. To achieve the above reason, proniosomes were prepared and optimized utilizing Box-Behnken design. The ideal formulation was chosen by a point prediction method and formulation showed vesicle size of 562 ± 1.223 nm, entrapment efficiency of GLB & ATN 97.037 ± 1.43% and 96.230 ± 1.62% respectively which were found in concurrence with the predicted value. The optimized combinational proniosomal gel (OCPG) formulation was additionally assessed for in vitro drug release, In vitro drug permeation, and in vivo pharmacokinetic study. The OCPG formulation shows the greatest flux over the rabbit skin (128.609 ± 2.24 mg/cm/h and 322.054 ± 1.53 mg/ cm/h) of GLB and ATN respectively. The results indicated desired release and permeation profiles. OCPG showed significantly (p < 0.001) pharmacokinetic contemplate exhibited that transdermal proniosomal formulation demonstrated improvement in bioavailability of two drugs 129.30 and 174.62 times respectively as that of the oral formulation. Overall the results show that controlled release GLB and ATN provesicles offer a useful and promising transdermal delivery system for the treatment of type II diabetes and hypertension by using design. Henceforth this may be an achievement in treating diabetic hypertensive patient.